Amniotic Fluid-Derived Cells: An Autologous Cell Source for Cardiovascular Tissue Engineering
- 19 July 2014
- book chapter
- Published by Springer Nature
- p. 99-105
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Tissue-Engineered Vascular Grafts for Use in the Treatment of Congenital Heart Disease: From the Bench to the Clinic and Back AgainRegenerative Medicine, 2012
- Stem cell therapy independent of stemnessWorld Journal of Stem Cells, 2012
- A critical role for macrophages in neovessel formation and the development of stenosis in tissue‐engineered vascular graftsThe FASEB Journal, 2011
- Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challengesEuropean Heart Journal, 2011
- Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacementPatient Preference and Adherence, 2011
- Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodelingProceedings of the National Academy of Sciences of the United States of America, 2010
- FLUID MECHANICS OF ARTIFICIAL HEART VALVESClinical and Experimental Pharmacology and Physiology, 2009
- Tissue-engineered Vascular Grafts Demonstrate Evidence of Growth and Development When Implanted in a Juvenile Animal ModelAnnals of Surgery, 2008
- Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical applicationHaematologica, 2008
- Isolation of amniotic stem cell lines with potential for therapyNature Biotechnology, 2007